People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ImmunoGenesis, Inc. | — | Biotechnology | Series C | $50.2M | $42.9M | 2024 |
Michael Curran at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Curran on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Stein | 1 | 6 |
| Robert B. Stein | 1 | 5 |
| Clifford Stocks | 1 | 5 |
| TED KOUTOUZIS | 1 | 4 |
| Thomas Barton | 1 | 4 |
| Federica Pericle | 1 | 2 |
| Federica O'Brien | 1 | 2 |
| Jennifer Barlow | 1 | 1 |
| Clifford B. Stocks | 1 | 1 |
| Thomas A. Barton | 1 | 1 |
| James Barlow | 1 | 1 |
| Jeremy Barton | 1 | 1 |
| Michael A. Curran | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.